C-type natriuretic peptide

Peptides

Volumn 17, Issue 7, 1996, Pages 1243-1251

  Barr, Craig S ^a   Rhodes, Peter ^b   Struthers, Allan D ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b NONE

Author keywords

atrial natriuretic peptide; B type natriuretic peptide; C type natriuretic peptide; vascular natriuretic peptide system

Indexed keywords

ATRIAL NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C;

ANIMAL TISSUE; CENTRAL NERVOUS SYSTEM; ENDOTHELIUM; HEART; INTESTINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; UROGENITAL SYSTEM;

ANIMALS; HUMANS; NATRIURETIC PEPTIDE, C-TYPE; PROTEINS;

ANIMALIA;

EID: 0029907688     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(96)00110-6     Document Type: Review

References (81)

1. 1. Akabane, S.; Matsushima, Y.; Matsuo, H.; Kawamura, M.; Imanishi, M.; Omea, T. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney. Eur. J. Pharmacol. 198:143-146; 1991.
2. 2. Anand Srivastava, M. B.; Sairam, M. R.; Cartin, M. Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. J. Biol. Chem. 265:8566-8572; 1990.
3. 3. Anderson, J. V.; Struthers, A. D.; Payne, N. N.; Slater, J. D. H.; Bloom, S. R. Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man. Clin. Sci. 70:507-512; 1986.
4. 4. Atarashi, K.; Mulrow, P. J.; Franco-Seanz, R.; Snajdar, R.; Rapp, J. Inhibition of aldosterone production by an atrial extract. Science 224:992-994; 1984.
5. 5. Barr, C. S.; Cargill, R. I.; Coutie, W. J.; Struthers, A. D.; Lipworth, B. J. C-type natriuretic peptide in heart failure and pulmonary heart disease. Br. Heart J. 71:P73 (abstract); 1994.
6. 6. Barr, C. S.; Davidson, N. C.; Struthers, A. D. Cardiovascular and neuroendocrine effects of CNP in healthy man. J. Hum. Hypertens. 8:655-656 (abstract); 1994.
7. 7. Bennett, B. D.; Bennett, G. L.; Vitangcol, R. V.; Jewett, J. R.; Burnier, J.; Henzel, W.; Lowe, D. G. Extracellular domain - IgG fusion proteins for three human natriuretic peptide receptors. J. Biol. Chem. 266:23060-23067; 1991.
8. 8. Bjenning, C.; Takei, Y.; Watanabe, T. K.; Nakajima, K.; Sakakibara, S.; Hazon, N. A C-type natriuretic peptide is a vasodilator in vivo and in vitro in the common dogfish. J. Endocrinol. 133:R1-R4; 1992.
9. 9. Brandt, R. R.; Aarhus, L. L.; Lewicki, J. A.; Burnett, J. C., Jr. Clearance receptor mechanisms in the regulation of the endothelial cell-derived vasoactive C-type natriuretic peptide. Circulation 88:I-182 (abstract); 1993.
10. 10. Brown, J.; Zuo, Z. Renal receptors for atrial and C-type natriuretic peptide in the rat. Am. J. Physiol. 263:F89-F96; 1992.
11. 11. Brown, J.; Zuo, Z. C-type natriuretic peptide and atrial natriuretic peptide receptors of rat brain. Am. J. Physiol. 264:R513-R523; 1993.
12. 12. Burnett, J.C., Jr.; Granger, J. P.; Opgenorth, T. J. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am. J. Physiol. 247:F863-F866; 1984.
13. 13. Campbell, W. B.; Currie, M. G.; Needleman, P. Inhibition of aldosterone biosynthesis by atriopeptins in rat adrenal cells. Circ. Res. 57:113-118; 1985.
14. 14. Canaan-Kuhl, S.; Jamieson, R. L.; Myers, B. D.; Pratt, R. E. Identification of "B" receptor for natriuretic peptide in human kidney. Endocrinology 130:550-552; 1992.
15. 15. Chang, M. S.; Lowe, D. G.; Lewis, M.; Hellmiss, R.; Chen, E.; Goeddel, D. V. Differential activation by atrial and brain natriuretic peptides of two different guanylate cyclases. Nature 341:68-72; 1989.
16. 16. Charles, C. J.; Richards, A. M.; Espiner, E. A. Central C-type natriuretic peptide but not atrial natriuretic factor lower blood pressure and adrenocortical secretion in normal conscious sheep. Endocrinology 131:1721-1726; 1992.
17. 17. Cheung, B. M.; Brown, M. J. Plasma brain natriuretic peptide and c-type natriuretic peptide in essential hypertension. J. Hypertens. 12:449-454; 1994.
18. 18. Chinkers, M.; Garbers, D. L. The protein kinase domain of the ANP receptor is required for signalling. Science 245:1392-1394; 1989.
19. 19. Chinkers, M.; Garbers, D. L.; Chang, M. S.; Lowe, D. G.; Chin, H.; Goeddel, D. V.; Schulz, S. A membrane form of guanylate cyclase is an atrial peptide receptor. Nature 338:78-83; 1989.
20. 20. Chrisman, T. D.; Schulz, S.; Potter, L. R.; Garbers, D. L. Seminal plasma factors that cause large elevations in cellular cyclic GMP are C-type natriuretic peptides. J. Biol. Chem. 268:3698-3703; 1993.
21. 21. Clavell, A. L.; Stingo, A. J.; Wei, C. M.; Heublein, D. M.; Burnett, J. C., Jr. C-type natriuretic peptide: a selective cardiovascular peptide. Am. J. Physiol. 264:R290-R295; 1993.
22. 22. Currie, M. G.; Geller, D. M.; Cole, B. R.; et al. Purification and sequence analysis of bioactive atrial peptides (atriopeptins). Science 223:67-69; 1984.
23. 23. Currie, M. G.; Fok, K. F.; Kato, J.; Moore, R. J.; Hamra, F. K.; Duffin, K. L.; Smith, C. E. Guanylin: An endogenous activator of intestinal guanylate cyclase. Proc. Natl. Acad. Sci. USA 89:947-951; 1992.
24. 24. Drewett, J. G.; Ziegler, R. J.; Trachte, G. J. Neuromodulatory effects of atrial natriuretic factor are independant of guanylate cyclase in adrenergic neuronal phaeochromocytoma cells. J. Pharmacol. Exp. Ther. 255:497-503; 1990.
25. 25. Eguchi, S.; Hirata, Y.; Imai, T.; Marumo, F. C-type natriuretic peptide upregulates vascular endothelin type B receptors. Hypertension 23(pt. 2):936-946; 1994.
26. 26. Evans, D. H.; Toop, T.; Donald, J.; Forrest, J. N., Jr. C-type natriuretic peptides are potent dilators of shark vascular smooth muscle. J. Exp. Zool. 265:84-87; 1993.
27. 27. Fuller, F.; Porten, J. G.; Arfsten, A. E.; et al. Atrial natriuretic peptide clearance receptor. J. Biol. Chem. 263:9395-9401; 1988.
28. 28. Furuya, M.; Yoshida, M.; Hayashi, Y.; et al. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 177:927-931; 1991.
29. 29. Furuya, M.; Aisaka, K.; Miyazaki, T.; et al. C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem. Biophys. Res. Commun. 193:248-253; 1993.
30. 30. Furuya, M.; Tawaragi, Y.; Minamitake, Y.; et al. Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 183:964-969; 1992.
31. 31. Geary, C. A.; Goy, M. F.; Boucher, R. C. Synthesis and vectorial export of cGMP in airway epithelium: Expression of soluble and CNP-specific guanylate cyclase. Am. J. Physiol. 265:L598-L605; 1993.
32. 32. Gunning, M.; Cuero, C.; Solomon, R.; Silva, P. C-type natriuretic peptide receptors and signalling in rectal gland of Squalus acanthias. Am. J. Physiol. 264:F300-F305; 1993.
33. 33. Haas, M.; Kopin, I. J.; Goldstein, D. S.; Zukowska-Grojec, Z. Differential inhibition of alpha adrenoceptor-mediated pressor responses by rat atrial natriuretic peptide in the pithed rat. J. Pharmacol. Exp. Ther. 235:122-127; 1985.
34. 34. Hama, N.; Itoh, H.; Shirakami, G.; et al. Detection of c-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients. Biochem. Biophys. Res. Commun. 198:1177-1182; 1994.
35. 35. Hashiguchi, T.; Higuchi, K.; Ohashi, M.; Takayanagi, R.; Matsuo, H.; Nawata, H. Effect of porcine brain natriuretic peptide (pBNP) on human adrenal steroidogenesis. Clin. Endocrinol. 31:623-360; 1989.
36. 36. Henrich, W. L.; McAllister, E. A.; Smith, P. B.; Lipton, J.; Campbell, W. B. Direct inhibitory effect of atriopeptin III on renin release in primate kidney. Life Sci. 41:259-264; 1987.
37. 37. Heublein, D. M.; Clavell, A. L.; Stingo, A. J.; Lerman, A.; Wold, L.; Burnett, J. C., Jr. C-type natriuretic peptide immunoreactivity in human breast endothelial cells. Peptides 13:1017-1019; 1990.
38. 38. Hirata, M.; Chang, C. H.; Murad, F. Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells. Biochim. Biophys. Acta 1010:346-351; 1989.
39. 39. Holmes, S. J.; Espiner, E. A.; Richards, A. M.; Yandle, T. G.; Frampton, C. Renal, endocrine and haemodynamic effects of human brain natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 76:91-96; 1993.
40. 40. Hu, R. M.; Levin, E. R.; Pedram, A.; Frank, H. J. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells. Mediation through the C receptor. J. Biol. Chem. 267:17384-17389; 1992.
41. 41. Huang, F. L. S.; Skala, K. D.; Samson, W. K. Hypothalamic effects of C-type natriuretic peptide (CNP) on luteinizing hormone secretion. J. Neuroendocrinol. 4:325-330; 1992.
42. 42. Hunt, P. J.; Richards, A. M.; Espiner, E. A.; Nicholls, M. G.; Yandle, T. G. Bioactivity and metabolism of c-type natriuretic peptide in normal man. J. Clin. Endocrinol. Metab. 78:1428-1435; 1994.
43. 2+ conductance and reduces cellular cAMP via a cGMP-independent mechanism. Am. J. Physiol. 263:C334-C342; 1992.
44. 44. Itoh, H.; Pratt, R. E.; Dzau, V. J. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J. Clin. Invest. 86:1690-1697; 1990.
45. 45. Itoh, H.; Pratt, R. E.; Dzau, V. J. Atrial natriuretic factor as a novel antigrowth factor of endothelial cells. Hypertension 19:758-761; 1992.
46. 2 in rabbit isolated vasa deferentia. J. Pharmacol. Exp. Ther. 257:720-726; 1991.
47. 47. Kaneko, O.; Shirakami, G.; Nakao, K.; et al. C-type natriuretic peptide (CNP) is the major natriuretic peptide in human cerebrospinal fluid. Brain Res. 612:104-109; 1993.
48. 48. Kenny, A. J.; Stephenson, S. L. Role of endopeptidase 24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett. 232:1-8; 1988.
49. 49. Kenny, A. J.; Bourne, A.; Ingram, J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase 24.11. Biochem. J. 291:83-88; 1993.
50. B in vascular smooth muscle cells. Am. J. Physiol. 265:H1373-H1379; 1993.
51. 51. Kobayashi, H.; Mizuki, T.; Tsutsui, M.; Minami, K.; Yanagihara, N.; Yuhi, T.; Izumi, F. Receptors for C-type natriuretic peptide in cultured rat glial cells. Brain Res. 617:163-166; 1993.
52. 52. Kojima, M.; Minamino, N.; Kangawa, K.; Matsuo, H. Cloning and sequence analysis of a cDNA encoding a precursor for rat C-type natriuretic peptide (CNP). FEBS Lett. 276:209-213; 1990.
53. 53. Kohno, M.; Yasunari, K.; Yokokawa, K.; Murakawa, K.; Horio, T.; Takeda, T. Inhibition by atrial and brain natriuretic peptide of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J. Clin. Invest. 87:1999-2004; 1991.
54. 54. Kohno, M.; Horio, T.; Yokokawa, K.; Kurihara, N.; Takeda, T. C-type natriuretic peptide inhibits thrombin-and angiotensin II-stimulated endothelin release via cyclic guanosine 3′, 5′-monophosphate. Hypertension 19:320-325; 1992.
55. 55. Kohno, M.; Horio, T.; Ikeda, M.; et al. Natriuretic peptides inhibit mesangial cell production of endothelin induced by arginine vasopressin. Am. J. Physiol. 264:F678-F683; 1993.
56. 56. Koller, K. J.; Lowe, D. G.; Bennett, G. L.; Minamino, N.; Kangawa, K.; Matsuo, H.; Goeddel, D. V. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 252:120-123; 1991.
57. 57. Koller, K. J.; de Sauvage, F. J.; Lowe, D. G.; Goeddel, D. V. Conservation of the kinase-like regulatory domain is essential for activation of the natriuretic peptide receptor guanylyl cyclases. Mol. Cell. Biol. 12:2581-2590; 1992.
58. 58. Komatsu, Y.; Nakao, K.; Suga, S.; et al. C-type natriuretic peptide in rats and humans. Endocrinology 129:1104-1106; 1991.
59. 59. Komatsu, U.; Nakao, K.; Itoh, H.; Suga, S.; Ogawa, Y.; Imura, H. Vascular natriuretic peptide. Lancet 34:622 (letter); 1992.
60. 60. Lang, C. C.; Choy, A.-M. J.; Struthers, A. D. Atrial and brain natriuretic petides: A dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin. Sci. 83:519-527; 1992.
61. 61. Lippton, H.; Hao, Q.; Hyman, A. Pulmonary vasodilator properties of natriuretic peptides. Circulation 86:I-604 (abstract); 1992.
62. 62. Mantovani, A.; Bussolino, F.; Dejana, E. Cytokine regulation of endothelial function. FASEB J. 6:2591-2599; 1992.
63. 63. Maack, T.; Suzuki, M.; Almeida, F. A.; et al. Physiological role of silent receptors of atrial natriuretic factor. Science 238:675-678; 1987.
64. 64. Margulies, K. B.; Heublein, D. M.; Perella, D. M.; Burnett, J. C., Jr. ANF-mediated renal mediated cGMP generation in congestive heart failure. Am. J. Physiol. 260:F562-F568; 1991.
65. 65. Margulis, A.; G raczniak, R. M.; Duda, T.; Sharma, R. K.; Sitaramayya, A. Structural and biochemical identity of retinal rod outer segment membrane guanylate cyclase. Biochem. Biophys. Res. Commun. 194:855-861; 1993.
66. 66. Mattingly, M. T.; Brandt, R. R.; Heublein, D. M.; Wei, C. M.; Nir, A.; Burnett, J. C., Jr. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int. 46:744-747; 1994.
67. 67. McArdle, C. A.; Poch, A.; Kappler, K. Cyclic guanosine monophosphate production in the pituatary: Stimulation by C-type natriuretic peptide and inhibition by gonadotrophin-releasing hormone in α T3-1 cells. Endocrinology 132:2065-2072; 1993.
68. 68. McGregor, A.; Richards, M.; Espiner, E.; Yandle, T.; Ikram, H. Brain natriuretic peptide adminstered to man: Actions and metabolism. J. Clin. Endocrinol. Metab. 70:1103-1107; 1990.
69. 69. McMurray, J. J.; Coutie, W. J. R.; McFarlane, L.; Struthers, A. D. Atrial natriuretic factor inhibits ACTH stimulated aldosterone but not cortisol secretion in man. Eur. J. Clin. Pharmacol. 35:409-412; 1988.
70. 70. Minamino, N.; Kangawa, K.; Matsuo, H. N-terminally extended form of C-type natriuretic peptide (CNP-53) identified in porcine brain. Biochem. Biophys. Res. Commun. 170:973-979; 1990.
71. 71. Minamino, N.; Makino, Y.; Tateyama, H.; Kangawa, K.; Matsuo, H. Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem. Biophys. Res. Commun. 179:535-542; 1991.
72. 72. Morita, H.;, Hagiike, M.; Horiba, T.; et al. Effects of brain natriuretic peptide and C-type natriuretic peptide infusion on urine flow and jejunal absorption in anesthetised dogs. Jpn. J. Physiol. 42:349-353; 1992.
73. 73. Muller, D.; Schulze, C.; Banmeister, H.; Buck, F.; Richter, D. Rat insulin-degrading enzyme: Cleavage pattern of the natriuretic peptide hormones ANP, BNP and CNP revealed by HPLC and mass spectrometry. Biochemistry 31:11138-11143; 1992.
74. 74. Nakamaru, M.; Inagami, T. Atrial natriuretic factor inhibits norepinephrine release evoked by sympathetic nerve stimulation in isolated perfused rat mesenteric arteries. Eur. J. Pharmacol. 123:459-461; 1986.
75. 75. Nakamura, M.; Arakawa, N.; Funakoshi, T.; Yoshida, H.; Hiramori, K. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels is distinct from atrial natriuretic peptide in patients with chronic heart failure. Circulation 90:1210-1214; 1994.
76. 76. Neuser, D.; Stasch, J. P.; Knorr, A.; Kazda, S. Inhibition of atrial natriuretic peptide of endothelin-1 stimulated proliferation of vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 22:S257-S261; 1993.
77. 77. Nunez, D. J. R.; Dickson, C. M.; Brown, K. J. Natriuretic peptide receptor mRNAs in the rat and human heart. J. Clin. Invest. 90:1966-1971; 1992.
78. 78. Nuzzenzeig, D. R.; Lewicki, J. A.; Maack, T. Celllular mechanisms of type c receptors of atrial natriuretic factor. J. Biol. Chem. 265:20952-20958; 1990.
79. 79. Ogawa, Y.; Nakao, K.; Nakagawa, O.; et al. Human C-type natriuretic peptide. Characterization of the gene and peptide. Hypertension 19:809-813; 1992.
80. 80. Porter, J. G.; Catalano, R.; McEnroe, G.; Lewicki, J. A.; Protter, A. A. C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. Am. J. Physiol. 263:C1001-C1006; 1992.
81. 81. Richards, A. M.; Crozier, I. G.; Holmes, S. J.; Espiner, E. A.; Yandle, T. G.; Frampton, C. Brain natriuretic peptide: Natriuretic and endocrine effects in essential hypertension. J. Hypertens. 11:163-170; 1993.